AVT vs NVDA

AVT's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial health. The Graham Number suggests a defensive fair value of $59.95, implying the current price of $50.83 is slightly undervalued, though growth-based intrinsic value is much lower at $18.76. Profitability metrics are weak, with low margins and declining earnings, but the balance sheet shows strength via a solid current ratio and moderate leverage. Despite mixed signals, the stock appears fairly valued with moderate risks and limited near-term catalysts.

NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.